Beyond these commonly reported adverse effects, it is crucial to evaluate the impact of PPAR-δ agonists on cardiovascular risk, particularly in patients with preexisting dyslipidemia or hypertension, given their established role in lipid metabolism [28]. The gene discussed is PPARD; the disease is hypertensive disorder.